2025
Proof-of-concept study in UAE (~100 participants)
2024
ISO 13485 certification of Quality Management System
2023
HiPAL Pro listing with FDA [510(k) Exempt]
2020
2019
Research study in Malaysia (~200 participants)
2015-2019
Research study in UK (~120 participants)
2016-2018
Exploratory non-interventional clinical trial in USA, Canada and UK (~600 participants)
Majority of participants in USA, participants from two groups [diagnosed with AD, healthy volunteers]
2017
Research study in UK with young adults (~20 participants)
2012
Genting TauRx Diagnostic Centre Sdn Bhd, a company established in Malaysia, and its wholly owned subsidiary GT Diagnostics (UK) Limited (collectively, “GT Diagnostics”, “our”) was founded as a collaboration between Genting Berhad, a Malaysian company, and TauRx Pharmaceuticals Ltd Group, with the vision to change the diagnostic landscape and market in dementia.
Our mission is to provide the missing tools for early diagnosis and monitoring of disease progression in dementia; tools that can be used in the comfort of one’s home, to tools that require administration by experts.
